These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17979937)

  • 1. Calcium supplements in patients with prostate cancer.
    Molokwu CN
    BJU Int; 2007 Dec; 100(6):1411. PubMed ID: 17979937
    [No Abstract]   [Full Text] [Related]  

  • 2. Nursing implications of androgen deprivation therapy-associated bone loss.
    Weingard KK
    Urol Nurs; 2006 Aug; 26(4):261-9; quiz 270. PubMed ID: 16939043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone complications: an increasing risk in patients with prostate cancer.
    J Support Oncol; 2007 Feb; 5(2):88-9. PubMed ID: 17348369
    [No Abstract]   [Full Text] [Related]  

  • 4. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bone and Men's Health. Hormonal therapy and bone loss in prostate cancer].
    Izumi K; Mizokami A; Namiki M
    Clin Calcium; 2010 Feb; 20(2):175-81. PubMed ID: 20118508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy.
    Bhoopalam N; Campbell SC; Moritz T; Broderick WR; Iyer P; Arcenas AG; Van Veldhuizen PJ; Friedman N; Reda D; Warren S; Garewal H
    J Urol; 2009 Nov; 182(5):2257-64. PubMed ID: 19758618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis from androgen deprivation therapy in prostate cancer treatment.
    McLeod N; Huynh CC; Rashid P
    Aust Fam Physician; 2006 Apr; 35(4):243-5. PubMed ID: 16642243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The if's, and's, or but's regarding bisphosphonates for prostate cancer.
    Wilt TJ; Ensrud KE
    J Natl Cancer Inst; 2007 May; 99(10):744-5. PubMed ID: 17505065
    [No Abstract]   [Full Text] [Related]  

  • 9. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
    Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
    BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone loss in prostate cancer: evaluation, treatment and prevention.
    Saad F
    Can J Urol; 2005 Feb; 12 Suppl 1():71-6; discussion 99-100. PubMed ID: 15780171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
    Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
    Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone mineral density changes on androgen deprivation therapy for prostate cancer and response to antiresorptive therapy.
    Yaturu S; DjeDjos S; Alferos G; Deprisco C
    Prostate Cancer Prostatic Dis; 2006; 9(1):35-8. PubMed ID: 16276350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer treatment-induced bone loss.
    Adler RA
    Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):442-5. PubMed ID: 17982349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of insolation on osteoporosis progression in androgen deprived nonmetastatic prostate cancer patients.
    Spanjol J; Maricić A; Valencić M; Oguić R; Krpina K; Protić A; Ivancić A; Bobinac M; Fuckar D; Vojniković B
    Coll Antropol; 2008 Oct; 32 Suppl 2():79-81. PubMed ID: 19138011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporosis due to androgen suppression therapy in men with prostate cancer].
    Roux C
    Prog Urol; 2003 Apr; 13(2 Suppl 1):24-7. PubMed ID: 12815806
    [No Abstract]   [Full Text] [Related]  

  • 17. [Osteoporosis prophylaxis in men? Adverse effects of total androgen blockade in carcinoma of the prostate].
    Hüfner M
    Internist (Berl); 1999 Aug; 40(8):883. PubMed ID: 10476490
    [No Abstract]   [Full Text] [Related]  

  • 18. Practical guide to the management of osteoporosis in men with prostate cancer receiving androgen-deprivation therapy.
    Bruder JM
    Curr Urol Rep; 2005 May; 6(3):157-8. PubMed ID: 15869718
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
    Ishizaka K; Machida T; Kobayashi S; Kanbe N; Kitahara S; Yoshida K
    Int J Urol; 2007 Dec; 14(12):1071-5. PubMed ID: 18036042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.